There are 2789 resources available
674P - WITNESS: Real-world outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with nivolumab in France and subgroup analysis of patients receiving concomitant medications at baseline
Presenter: Antoine Thiery-Vuillemin
Session: ePoster Display
675P - Changes in treatment patterns and survival in renal cell carcinoma (RCC) patients in Norway: A nationwide registry study for 1995-2018
Presenter: Katarina Puco
Session: ePoster Display
641TiP - Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H
Presenter: Johann de Bono
Session: ePoster Display
600P - Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Scott Tagawa
Session: ePoster Display
602P - Prevalence of castration-resistant prostate cancer (CRPC) of unknown metastatic status in the real-world setting: The AfrODiTA study
Presenter: Miguel Rodrigo-Aliaga
Session: ePoster Display
603P - Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial
Presenter: Emeline Colomba
Session: ePoster Display
604P - Predictive genomic biomarkers in non-metastatic castration resistant prostate cancer (nmCRPC) treated with androgen receptor pathway inhibitors (ARPi)
Presenter: Richard Gagnon
Session: ePoster Display
605P - Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide
Presenter: Ravi Madan
Session: ePoster Display